Pylopass to Launch in the US
14 Nov 2016 --- The nutritional ingredient, Pylopass is set to launch in the US, according to Organobalance, it’s German biotechnology manufacturer, and Maypro Industries, its sole US distributor.
Life Extension will be launching Gastro-Ease, a dietary supplement containing Pylopass to the US public this November.
Organobalance developed this patented bioactive against the stomach bacterium Helicobacter pylori, a gram-negative, spiral shaped bacteria that colonizes in the stomach, using a natural lactic acid bacterium from its microorganisms strain collection made from spray-dried inactivated cells of Lactobacillus reuteri.
Helicobacter pylori can cause digestive issues and the bacteria used in Pylopass secretes enzymes that neutralize stomach acid, creating a fit environment for it to survive and “burrow” through the stomach lining.
According to the Center for Disease Control and Prevention (CDC), it is estimated that two thirds of the world’s population is infected with Helicobacter pylori.
“Pylopass has a unique effect against this carcinogenic stomach bacterium”, emphasizes Prof. Dr. Christine Lang, microbiologist and Organobalance’s managing director.
“Unlike conventional therapies involving antibiotics which can harm the human microbiome, consumers who are taking Pylopass can lower their Helicobacter pylori load without losing their natural bacterial balance in their gut.”
Many customers worldwide already use this ingredient in dietary supplements but Life Extension is the first company to launch this Self-affirmed GRAS, Non-GMO, and shelf stable ingredient on the US market.
